Patents by Inventor Henrik Ørum

Henrik Ørum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150368642
    Abstract: The invention provides LNA therapeutics oligonucleotide carbohydrate conjugates with considerably enhanced potency, extended therapeutic index and reduced toxicity.
    Type: Application
    Filed: January 30, 2014
    Publication date: December 24, 2015
    Inventors: Nanna ALBÆK, Henrik Frydenlund HANSEN, Susanne KAMMLER, Jacob RAVN, Henrik ØRUM, Mark TURNER, Monika KRAMPERT, Philipp HADWIGER, Søren OTTOSEN, Morten LINDOW
  • Patent number: 8653252
    Abstract: The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.
    Type: Grant
    Filed: March 22, 2004
    Date of Patent: February 18, 2014
    Assignee: Santaris Pharma A/S
    Inventors: Joachim Elmén, Claes Wahlestedt, Zicai Liang, Anders Malling Sørensen, Henrik Ørum, Troels Koch
  • Publication number: 20120040917
    Abstract: The present invention relates to compositions and methods for preparing splice variants of TNFalpha receptor (TNFR) in vivo or in vitro, and the resulting TNFR protein variants. Such variants may be prepared by controlling the splicing of pre-mRNA molecules and regulating protein expression with splice switching oligonucleotides or splice switching oligomers (SSOs). The preferred SSOs according to the invention target exon 7 or 8 of TNFR1 (TNFRSF1A) or TNFR2 (TNFRSF1A) pre-mRNA, typically resulting in the production of TNFR variants which comprise a deletion in part or the entire exon 7 or 8 respectfully. SSOs targeting exon 7 are found to result in a soluble form of the TNFR, which has therapeutic benefit for treatment of inflammatory diseases. The SSO's are characterized in that they are substantially incapable or incapable of recruiting RNaseH.
    Type: Application
    Filed: December 3, 2010
    Publication date: February 16, 2012
    Inventors: HENRIK ØRUM, PETER L. SAZANI
  • Patent number: 7785834
    Abstract: The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: August 31, 2010
    Assignees: Ercole Biotech, Inc., University of North Carolina at Chapel Hill, Santaris Pharma A/S
    Inventors: Peter L. Sazani, Maria Graziewicz, Ryszard Kole, Henrik Ørum
  • Patent number: 7682786
    Abstract: A method for specifically determining the presence of a target by contacting said target in the presence of other targets with a probe capable of binding to said target to form a complex of said target with said probe, wherein the contacting is performed in the presence of a compound enhancing the specificity of said binding or the complex formed is contacted with a compound enhancing the specificity of said binding. This method opens the way to a better discrimination between related nucleic acid sequences in diagnostic assays.
    Type: Grant
    Filed: March 4, 1996
    Date of Patent: March 23, 2010
    Inventors: Henrik Ørum, Ane-Ullerup Lester
  • Patent number: 7125972
    Abstract: A method for the detection of point mutation and polymorphisms in nucleic acids or for sequencing of unknown nucleic acids by a simple procedure using arrays uses nucleic acid analoges as sequence discriminators. This procedure simplifies the working mode in complex problematic cases.
    Type: Grant
    Filed: August 29, 2002
    Date of Patent: October 24, 2006
    Assignee: Boston Probes, Inc.
    Inventors: Jörg Kleiber, Henrik Ørum, Ane-Ullerup Lester, Albert Geiger
  • Patent number: 6475721
    Abstract: A method for the detection of point mutation and polymorphisms in nucleic acids or for sequencing of unknown nucleic acids by a simple procedure using arrays uses nucleic acid analoges as sequence discriminators. This procedure simplifies the working mode in complex problematic cases.
    Type: Grant
    Filed: November 12, 1997
    Date of Patent: November 5, 2002
    Assignee: Boston Probes, Inc.
    Inventors: Jörg Kleiber, Henrik Ørum, Ane-Ullerup Lester, Albert Geiger
  • Patent number: 6326143
    Abstract: The present invention concerns a method for generating multiple double stranded nucleic acids by (a) elongating a primer molecule comprising a nucleobase sequence B′ by using one or more nucleotide(s) and a target nucleic acid T that acts as a template for the elongation of said primer such that the elongation product E formed is capable of acting as a template for the elongation of a further primer molecule containing the nucleobase sequence B′; (b) separating the target nucleic acid T from said elongation product E; (c) using said elongation product E as a template for the elongation of a further primer molecule yielding an elongation product E′; and (d) repeating the steps of elongating primer molecules and of separating said elongation products a sufficient number of times to achieve the desired amount of double stranded nucleic acid.
    Type: Grant
    Filed: May 22, 1998
    Date of Patent: December 4, 2001
    Assignee: Roche Diagnostics GmbH
    Inventors: Henrik Ørum, Corina Seeger